{
    "attributes": {
        "action": "Gilenya (fingolimod)",
        "additional_details": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGilenya MS pill denied by NICE\r\n05 Aug 2011\r\n\r\nThe National Institute for Health & Clinical Excellence (NICE), which advises the NHS on which treatments to provide, has issued draft guidance stating Gilenya (fingolimod) should not be made freely available on the NHS, because the treatment is not \u2018cost effective\u2019.\r\n\r\nIn clinical trials Gileyna has proved more effective than current injectable treatments.\r\n\r\nNICE compared Gilenya to \u2018best supportive care\u2019, which is when a patient takes no medicine for their condition, to rule it was not cost effective.\r\nNICE also failed to consider the broader social and economic benefits of medicines \u2013 like that a reduction in relapses will enable a person to remain in work for longer.\r\n\r\nSimon added: \u201cWe\u2019re concerned at how this decision has been reached and now strongly encourage NICE and Novartis [the makers of Gilenya] to work together to look at how the treatment can be better re-considered and evaluated.\u201d\r\n",
        "background": null,
        "closed_at": null,
        "created_at": "2011-08-19T16:33:18.000Z",
        "debate": null,
        "debate_outcome_at": null,
        "debate_threshold_reached_at": null,
        "government_response": null,
        "government_response_at": null,
        "moderation_threshold_reached_at": "2011-08-19T16:33:18.000Z",
        "opened_at": null,
        "rejected_at": "2017-06-21T15:07:51.304Z",
        "rejection": {
            "code": "no-action",
            "details": null
        },
        "response_threshold_reached_at": null,
        "scheduled_debate_date": null,
        "signature_count": 1,
        "state": "rejected",
        "updated_at": "2017-06-21T15:07:51.308Z"
    },
    "id": 13745,
    "links": {
        "self": "https://petition.parliament.uk/archived/petitions/13745.json"
    },
    "type": "archived-petition"
}